1. Home
  2. BEAT vs ATNM Comparison

BEAT vs ATNM Comparison

Compare BEAT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

N/A

Current Price

$0.42

Market Cap

27.7M

Sector

Technology

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.25

Market Cap

31.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAT
ATNM
Founded
2015
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
31.7M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
BEAT
ATNM
Price
$0.42
$1.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$5.63
$4.50
AVG Volume (30 Days)
299.1K
161.7K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
15.07
14.17
EPS
N/A
0.71
Revenue
N/A
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$315.97
N/A
P/E Ratio
N/A
$1.97
Revenue Growth
N/A
11.11
52 Week Low
$0.39
$0.74
52 Week High
$4.00
$1.74

Technical Indicators

Market Signals
Indicator
BEAT
ATNM
Relative Strength Index (RSI) 32.38 66.29
Support Level N/A $0.96
Resistance Level $0.52 $1.38
Average True Range (ATR) 0.03 0.08
MACD -0.00 0.03
Stochastic Oscillator 15.18 73.33

Price Performance

Historical Comparison
BEAT
ATNM

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: